Hospital Clinico San Carlos
Verified site
Madrid, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying treatments for metastatic colorectal cancer, which is a type of cancer that starts in the colon or rectum and spreads to other parts of the body. The study involves two sequences of treatment using combinations of chemotherapy and biologic drugs. The chemotherapy regimens are known as FOLFOX and FOLFIRI. FOLFOX includes drugs like folinic acid, oxaliplatin, and fluorouracil, while FOLFIRI includes folinic acid, irinotecan, and fluorouracil. The biologic drugs used in this study are panitumumab and bevacizumab, which are designed to target specific proteins involved in cancer growth.
The purpose of the study is to compare the effectiveness of two different sequences of these treatments. In the first sequence, patients receive FOLFOX combined with panitumumab, followed by FOLFIRI combined with bevacizumab. In the second sequence, patients receive FOLFOX combined with bevacizumab, followed by FOLFIRI combined with panitumumab. The study aims to determine which sequence is more effective in controlling the cancer over a period of 36 months.
Participants in the study will receive their treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the progression of the cancer and the overall survival of the patients over the course of the treatment. The trial will also assess the safety of the treatments by keeping track of any side effects experienced by the participants. The study is expected to continue until June 2025.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
12 criteria
28 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Madrid, Spain
Marbella, Spain
Madrid, Spain
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a cancer medicine given through a vein. In this trial, it is used as part of the FOLFIRI treatment plan to help slow or stop the growth of colorectal cancer cells.
is a cancer medicine given through a vein. It is part of the FOLFIRI and FOLFOX treatment plans and works by interfering with how cancer cells make new genetic material, which can help stop them from growing.
is a targeted cancer therapy given through a vein. It is designed to block a protein on some cancer cells that helps them grow, which may help the treatment work better in patients whose tumors match this treatment.
is a targeted cancer therapy given through a vein. It helps block the growth of new blood vessels that tumors need to grow and spread, which can help slow the cancer down.
is a cancer medicine given through a vein. It is part of the FOLFOX treatment plan and helps damage cancer cells so they cannot grow and divide as easily.
is given through a vein together with fluorouracil in the FOLFOX and FOLFIRI treatment plans. It helps fluorouracil work better against the cancer cells.
Irinotecan is given by intravenous infusion, which means it is delivered directly into a vein by a healthcare professional. It is an approved cancer medicine that is widely used in medical practice and studied in many clinical trials, especially for colorectal cancer. It is used to treat metastatic colorectal cancer and some other cancers because it helps slow or stop cancer growth by blocking an important enzyme called topoisomerase I, which cancer cells need to copy their DNA and divide. It belongs to the class of topoisomerase I inhibitors, a group of anticancer medicines that damage cancer cells more than normal cells during cell division.
Fluorouracil is given by intravenous infusion and is administered by a medical team in a clinic or hospital. It is a long-established and well-known cancer medicine that remains important in modern oncology and is supported by extensive medical literature, especially for colorectal cancer. It is used to treat metastatic colorectal cancer and other cancers because it interferes with the way cells make DNA and RNA, which slows the growth of rapidly dividing cancer cells. Fluorouracil is classified as an antimetabolite, a type of anticancer medicine that acts like a natural building block of cells and disrupts cell growth.
Panitumumab is given by intravenous infusion as a concentrated solution for infusion, usually under close medical supervision. It is an approved targeted cancer medicine and is well described in medical literature, mainly for use in colorectal cancer with wild-type RAS. It is used to treat metastatic colorectal cancer because it attaches to a protein on the surface of cancer cells called EGFR and blocks signals that tell the cells to grow and survive. Panitumumab belongs to the class of monoclonal antibodies and is a targeted therapy.
Bevacizumab is given by intravenous infusion and is administered by a healthcare professional. It is a well-established cancer medicine with broad use in clinical practice and strong support in medical literature, especially in solid tumors such as colorectal cancer. It is used to treat metastatic colorectal cancer because it blocks a protein called VEGF, which tumors use to form new blood vessels and get nutrients. Bevacizumab is classified as a monoclonal antibody and an anti-angiogenic medicine, meaning it helps stop tumors from building the blood supply they need to grow.
Oxaliplatin is given by intravenous infusion in a hospital or clinic setting. It is an approved and widely studied cancer medicine, especially in colorectal cancer treatment. It is used to treat metastatic colorectal cancer because it damages the cancer cell’s DNA, making it hard for the cell to copy itself and survive. Oxaliplatin belongs to the platinum-based anticancer medicines, a class that works by causing harmful links in DNA.
Folinic acid is given by intravenous infusion and is used as part of combination cancer treatment. It is a well-known medicine in clinical practice and medical literature, especially in regimens for colorectal cancer, where it is not used alone but helps other medicines work better. It is used to support treatment with fluorouracil because it increases fluorouracil’s effect on cancer cells by helping it bind more strongly to an enzyme needed for DNA making. Folinic acid is classified as a reduced folate, which is a vitamin-like substance used to enhance anticancer therapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.